It has been proposed that the Akt kinase pathway provides a regulatory mechanism to limit the inflammatory response. We examined the activation of Akt upon lipopolysaccharide (LPS) challenge in monocytes of patients with rheumatoid arthritis (RA) and correlated it with disease activity. Twelve subjects with recent-onset, DMARD-na€ ıve RA, thirteen patients with chronic, DMARD therapy-non-responding RA and 27 healthy volunteers provided whole blood samples for phosphospecific flow cytometric measurement of unstimulated and LPS-stimulated Akt phosphorylation at serine 473 in monocytes, determined in relative fluorescence units (RFU). Activation capability, that is responsiveness of monocytes, was determined as the difference between stimulated and unstimulated samples and compared between groups using Mann-Whitney test. CRP and ESR, swollen and tender joint counts, patients' global assessment of disease activity, DAS28 score and plasma IL-6 determined by ELISA were correlated with Akt activation using Spearman method. Median (interquartile range) Akt activation capability was significantly lower in DMARD-na€ ıve (379 RFU [285, 432], P = 0.016) and even lower in DMARD-non-responding RA (258 RFU [213, 338], P < 0.001), compared to healthy controls (505 RFU [408, 639]) and showed a negative correlation with swollen joint count (r = À0.48, CI À0.78 to À0.05, P = 0.014), CRP (r = À0.42, CI À0.80 to À0.02, P = 0.039) and plasma IL-6 levels (r = À0.44, CI À0.65 to À0.17, P = 0.001). In conclusion, Akt activation capability of monocytes is low in early untreated RA and even lower in chronic, DMARD-non-responding RA, suggesting a role for Akt pathway in the pathogenesis of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease causing severe joint destruction and disability if not responding to therapy. Although its pathogenesis is not completely understood, it is likely to develop by both adaptive (especially T cell-driven) and innate immune responses [1] . Among the latter, monocyte functions can profoundly affect many characteristic processes in RA, for example production of key inflammatory cytokines [2] , expansion of Th17 cells [3] , cartilage damage and bone erosions [4] and responsiveness to immune complexes [5] . Also, evidence is accumulating to show that Toll-like receptor (TLR)-mediated responses may drive inflammation and joint destruction in RA [6] . In response to TLR4 stimulation by bacterial lipopolysaccharide (LPS), production of proinflammatory cytokines is drastically increased in peripheral blood mononuclear cells from RA patients when compared to cells from patients with osteoarthritis or healthy controls [7] . Also, the severity of collagen-induced arthritis and cartilage destruction are significantly reduced in TLR4-deficient mice [8] . Further, baseline serum levels of the endogenous TLR4 ligands myeloid-related proteins 8 and 14 correlate with responsiveness to tumour necrosis factor-a (TNF-a) inhibitor therapy [9] .
Production of cytokines and other downstream effects of TLR activation are mediated via activation of intracellular kinase cascades, including the serine/threonine kinase Akt pathway [10, 11] . Akt activation in response to growth factors and cytokines is essential for monocyte survival [12] . The Akt pathway is also triggered by activation of TLR4 in monocytes and macrophages, and interestingly, the downstream effects of this activation are not exclusively proinflammatory. Instead, LPS-induced Akt activation has been shown to reduce the production of proinflammatory cytokines while increasing anti-inflammatory mediators [13, 14] . It has been proposed that the Akt pathway provides a regulatory mechanism to limit the inflammatory response [10] . Therefore, we designed this study for elucidating whether circulating monocytes of patients with RA show aberrant activation of Akt in response to LPS, and whether this activation capability is associated with inflammatory activity markers in the plasma (CRP and IL-6) and disease activity of RA.
Conventional disease-modifying antirheumatic drugs (DMARDs), either as monotherapy or a combination, are usually the first treatment option in recent-onset RA. Even though DMARDs are often effective, not all patients respond satisfactorily to them [15] . Biological therapies such as TNF-a inhibitors have further improved the outcome, although not being universally successful either [6] . The immunological mechanisms contributing to the individual differences in the progression of RA and treatment response are not well known. Intracellular kinases are being vigorously investigated with regard to drug development in RA. Usually, kinase inhibitors have shown promising anti-inflammatory efficacy [16] . However, little is known about functioning of the kinases that themselves exhibit anti-inflammatory potential, such as Akt, in patients with RA.
In this study we show, using a phosphospecific flow cytometric method, defects in LPS-stimulated activation of Akt in whole blood monocytes in patients with recentonset DMARD-na€ ıve RA and chronic DMARD-nonresponding RA. Akt phosphorylation capability was also found to be inversely associated with disease activity and plasma level of IL-6.
Subjects and methods
Subjects. The study comprised three subject groups. Twelve patients who had been newly diagnosed with RA and not received DMARDs or oral corticosteroids prior to blood sampling were the DMARD-na€ ıve RA group. In thirteen patients with persisting disease activity despite active treatment with several synthetic DMARDs, TNF-a inhibitor treatment was started according to EULAR recommendations [17] . They comprised the DMARD-nonresponding RA group and their blood samples were obtained before initiating TNF-a inhibitor therapy. The patients were recruited non-consecutively at the Division of Rheumatology, Helsinki University Central Hospital, from October 2010 to March 2012. The third group, consisting of 27 healthy subjects, was recruited among laboratory and hospital personnel who did not have autoimmune diseases or immunosuppressive medication.
All patients fulfilled the ACR/EULAR 2010 classification criteria for RA [17] . No other inclusion criteria, with respect to disease activity, for example, were employed. The study protocol was approved by the Ethical Review Board of the Joint Authority for the Hospital District of Helsinki and Uusimaa. An informed written consent was obtained from each patient.
Blood samples and stimulation with LPS. A blood sample was taken by venipuncture from the antecubital vein into a Falcon polypropylene tube (Becton Dickinson, Lincoln Park, NJ, USA) containing 1:10 pyrogen-free acid citrate dextrose solution A (ACD-A; Baxter Healthcare Ltd, Norfolk, UK). Two 100 ll aliquots of blood were put into polystyrene tubes (BD) and supplemented with anti-CD14-FITC (BD, clone MΦP9, mouse IgG2b). Following a 5-min incubation at +37°C, one aliquot was stimulated with LPS (Escherichia coli O111:B4 LPS; Sigma, St. Louis, MO, USA) at final concentration of 100 ng/ml and the other was left unstimulated, and the tubes were further incubated for 10 min.
The rest of the blood sample was centrifuged to separate plasma, which was aliquoted and stored at À70°C until IL-6 determination.
Preparing leucocytes for flow cytometry. Incubated blood aliquots were prepared using a protocol and reagents by Becton Dickinson [18] . Briefly, leucocytes were fixed and erythrocytes lysed by adding Lyse/Fix Buffer. After pelleting, leucocytes were washed with stain buffer and permeabilized by Perm Buffer III at À20°C for 30 min. Cells were pelleted and washed with stain buffer, after which the tubes were supplemented with anti-Akt (pSer473)-PE antibody (clone M89-61, mouse IgG1j) in 100 ll of stain buffer. Following incubation at room temperature protected from light for 20 min, the cells were washed, resuspended in stain buffer and kept on ice for a maximum of 4 h until data acquisition by flow cytometer.
Optimal amounts of the antibodies and their compatibility with the permeabilization procedure, as well as optimal LPS stimulation conditions, were chosen based on preliminary experiments.
Flow cytometry. Monocyte flow cytometric data were acquired on FACSCantoII flow cytometer and analysed with FACSDiva software (BD Biosciences, San Jose, CA, USA). CD14-positive monocyte population was recognized on the basis of FITC fluorescence intensity (Fig. 1A) and light scattering properties (Fig. 1B) . Monocyte pAkt-PE fluorescence histogram was created, and fluorescence intensity was expressed as relative fluorescence units (RFU). Akt activation capability for each subject was determined by subtracting the RFU of the unstimulated sample (Fig. 1C) from that of the LPS-stimulated sample (Fig. 1D ). An electronic gate was set manually to include 2-4% of the cells in the unstimulated sample (Fig. 1C,  gate P6 ) and then copied to the fluorescence histogram of the stimulated sample (Fig. 1D) , enabling the estimation of the percentage of pAkt-positive cells following LPS stimulation.
IL-6 determination. IL-6 was determined by enzymelinked immunoassay (ELISA) using the reagents from eBioscience Inc (San Diego, CA, USA). The detection limit and interassay coefficient of variation were 0.39 pg/ml and 1.9%, respectively. Influence of rheumatoid factor and related endogenous antibodies with the IL-6 immunoassay was not found when assayed using commercially available heterophilic blocking agent HeteroBlock (Omega Biologicals, Bozeman, MT, USA) as recommended [19] with concentrations up to 600 lg/ml.
Statistical analysis. The data were presented as medians with interquartile ranges (IQR) or as counts with percentages. Statistically significant differences between the groups were tested by Kruskal-Wallis test, and P-values obtained by post hoc Mann-Whitney test are reported along with results. Correlations were estimated by Spearman's correlation coefficient method. STATA 13.1 (StataCorp LP, College Station, TX, USA) statistical package was used for the analyses.
Results
The patients' characteristics including disease activity data are shown in Table 1 . Consequently, pAkt activation capability ( Fig. 2A) Also, the proportion of pAkt-positive monocytes following LPS stimulation (Fig. 2B) was lower in DMARD-na€ ıve RA (37% [23, 43] , P = 0.003) and .......................................................................................................................................................... ..... The pAkt fluorescence intensity of the pAkt-positive monocytes did not, however, differ between groups (P = 0.063).
Akt activation capability in association with disease activity
Akt activation capability was negatively correlated with swollen joint count, IL-6 and CRP (Table 2 , Fig. 3 ).
Discussion
The results showed that Akt activation capability of whole blood monocytes upon LPS stimulation is significantly lower in patients with recent-onset DMARD-na€ ıve RA than in healthy subjects, and even lower in patients with DMARD-non-responding chronic RA. To our knowledge, the finding is novel. Our results are in good accordance with the hypothesis that the Akt pathway provides a regulatory mechanism to ensure transient expression of inflammatory mediators on LPS exposure [10] . Lower Akt phosphorylation capability of monocytes may indeed indicate a more active inflammatory state as demonstrated by its association with higher CRP and IL-6 levels and swollen joint counts in the present study. Defective Akt activation capability could result from the development of TLR4 desensitization which can be induced by LPS and endogenous proinflammatory TLR4 ligands [20] . It can be hypothesized whether there is an upper limit for Akt phosphorylation that becomes closer by higher background phosphorylation, favoured by the mediator milieu in the blood of RA patients. This could explain our finding that unstimulated monocyte Akt phosphorylation is higher while the phosphorylation capacity on LPS exposure is lower in recent-onset RA than in healthy subjects. In patients with chronic RA, the use of DMARDs may partly explain why the background phosphorylation of Akt was not higher than in healthy subjects [21, 22] . However, the proportion of monocytes in which Akt phosphorylation took place in response to LPS stimulation was lower in both patients with recent-onset RA and chronic RA than in healthy subjects, and pAkt fluorescence intensities of the pAkt-positive cells were similar in all groups, suggesting that the LPS-stimulated monocytes of the patients did not show the upper limit of Akt phosphorylation. Instead, it appears that the Akt phosphorylation capability of monocytes is aberrant in the patients, which may result from defective intracellular signalling or migration of potentially responsive monocytes to the inflamed joints. Recently, it has been reported that in LPS-stimulated peripheral blood mononuclear cells from patients with juvenile idiopathic arthritis, unlike in those from healthy donors, the regulation which increases Akt phosphorylation is markedly impaired [14] while TLR4 signal transduction is able to induce anti-inflammatory responses [10, 13, 14] involving Akt activation, the results suggest that this pathway is defective in patients with inflammatory arthritis. An intriguing possibility is that the defective Akt phosphorylation capability in RA may not be limited to TLR4 stimulation. For example, RA-associated immune complexes can inhibit monocyte apoptosis and activate monocytes via signalling pathways including the Akt pathway [23] . Thus, low Akt activation capability could interfere with appropriate monocyte activation and survival. Immunosuppressive effects of TLR2 stimulation and IL-10 are also mediated by the Akt pathway [24, 25] .
The proinflammatory effects mediated by the Akt signalling cascade, however, cannot be ignored. We have shown that inhibiting phosphatidylinositol 3-kinases (PI3Ks, located upstream of Akt in the cascade) represses the expression of proinflammatory mediators and Akt phosphorylation in LPS-stimulated macrophages and that the inhibitors reduce carrageenan-induced paw oedema in mice [26] . Nevertheless, effects of PI3K activation are not exactly the same as those of Akt activation [27] . It is also possible that in peripheral blood monocytes, higher Akt activation capability is advantageous in halting the development and/or perpetuation of arthritis.
Clearly, the mechanism and larger context of the aberrant Akt activation in RA warrant further studies. Measuring Akt activation capability in monocytes of RA patients receiving biological or kinase inhibitor treatment could be an interesting extension to the current study. In addition, a limitation of the current study warranting clarification in further research is that the monocytes' total amounts of the Akt protein, which could be different in RA patients and healthy subjects, were not determined.
To conclude, Akt phosphorylation in whole blood monocytes in response to LPS is significantly lower in patients with early untreated RA than in healthy subjects, and even lower in patients with chronic DMARD-non-responding RA. Depressed Akt activation may promote a state in which crucial Akt-mediated monocyte responses are impaired and contribute to the perpetuation of systemic inflammation.
